Pancreatic Cancer

A New Treatment for Advanced Pancreatic Cancer: What the RASolute 302 Trial Found

June 2026 · Camilo Correa, MD

For patients with pancreatic cancer that has already received treatment and continued to grow, the options have historically been very limited. A major phase 3 clinical trial published last week in the New England Journal of Medicine may change that picture in a meaningful way.

A Longstanding Problem

Pancreatic cancer is driven, in more than 90% of cases, by mutations in a gene called KRAS. This gene encodes for the KRAS protein, part of the RAS family of signaling proteins. When KRAS is mutated, the protein can become stuck in the “on” position, continuously sending growth signals that help cancer cells divide, survive, and spread. For decades, directly blocking KRAS was considered nearly impossible. Its structure gave drugs few obvious places to bind, and researchers called it “undruggable.”

That began to change with the development of a new class of drugs designed to lock onto the active (or “switched on”) form of mutant RAS and block it directly. These are not chemotherapy. They do not broadly attack all rapidly dividing cells. They are targeted agents, designed around the specific protein that is driving the cancer.

The Drug: Daraxonrasib

Daraxonrasib is an oral pill that inhibits the active, GTP-bound form of mutant and wild-type RAS. It belongs to a class called RAS(ON) multiselective tri-complex inhibitors. Being oral is a practical advantage for patients who are already spending considerable time in clinic for infusions and monitoring. The drug was developed by Revolution Medicines, which also funded the trial.

The Trial

RASolute 302 was a phase 3 international, open-label, randomized controlled trial. This is the type of study designed to determine whether a new treatment is actually better than the current standard of care. Five hundred patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), the most common type of pancreatic cancer, were enrolled. All had already received at least one prior line of treatment. Nearly 92% had a RAS G12 mutation, which is the mutation daraxonrasib was designed to target.

Patients were randomly assigned to receive either daraxonrasib or chemotherapy chosen by their oncologist. The two primary outcomes the trial measured were overall survival (how long patients lived) and progression-free survival (how long until the cancer grew or spread further).

The Results

The results were striking by any standard for this disease, and particularly striking for a second-line setting where prior trials have shown limited benefit.

A note on what “median” means: median survival is the point at which half of patients in the trial were still alive. Half lived longer than the median, and half lived less. These numbers describe the group’s experience, not any individual’s outcome. Some patients do considerably better; some do not.

Side Effects

Daraxonrasib also compared favorably to chemotherapy in tolerability. Serious side effects (grade 3 or higher) occurred in 62% of patients on daraxonrasib, compared to 70% on chemotherapy. More importantly, only 1.2% of patients taking daraxonrasib had to stop treatment entirely because of side effects, compared to 11.2% in the chemotherapy group.

For patients managing an advanced illness, the ability to stay on treatment without significant interruptions matters. Discontinuation due to toxicity was nearly ten times lower with daraxonrasib.

What This Means

Second-line treatment (which refers to the therapies used when first choice of treatment is ineffective) for metastatic pancreatic cancer has not changed substantially in over a decade. Median survival with chemotherapy in this setting has consistently been around six months, with limited quality-of-life benefit. RASolute 302 is the first phase 3 trial to show a large, statistically significant survival benefit over chemotherapy in this population.

This result will likely redefine how oncologists approach second-line treatment decisions. As of early June 2026, daraxonrasib is not yet commercially available; it can be accessed through ongoing clinical trials or through compassionate use authorization for selected patients. Regulatory review is underway and approval is anticipated. Patients should ask their oncologist about eligibility for a trial or expanded access program.

It is also important to understand what this trial did not study. These results apply to patients with metastatic disease who have already received prior treatment. Research in other settings is actively underway: RASolute 303 is evaluating daraxonrasib as a first-line treatment for newly diagnosed metastatic pancreatic cancer, and RASolute 304 is studying it in patients who have had surgery and completed chemotherapy, asking whether it can reduce the risk of recurrence. Results from those trials will determine how broadly this drug can eventually be used.

For patients and families navigating this diagnosis, this is a genuine development: not a cure, and not applicable to every situation, but a meaningful advance in a disease that has needed one for a long time. In my view, the magnitude of the survival benefit seen in RASolute 302 is the most significant result in second-line pancreatic cancer in over a decade.

Frequently Asked Questions

Does this trial apply to all patients with pancreatic cancer?

No. RASolute 302 enrolled patients with metastatic pancreatic cancer (stage IV) who had already received and progressed on prior chemotherapy. The results do not currently apply to patients with earlier-stage disease, those who have not yet started treatment, or those who have undergone surgery with curative intent. Additional trials are underway to evaluate daraxonrasib in those settings.

Do I need a specific genetic mutation to benefit?

Daraxonrasib was designed to target RAS mutations, and molecular profiling of your tumor is standard practice in pancreatic cancer care and remains important. In this trial, nearly 92% of patients had RAS G12 mutations, which reflects the typical pancreatic cancer population. What is notable is that the survival benefit was similarly strong across the entire trial population, regardless of exact mutational subtype. The prevailing view in the oncology community is that this drug will likely be used broadly in patients with metastatic pancreatic cancer rather than restricted to a narrow molecular subset. Your oncologist is the right person to assess whether your specific tumor profile makes you a candidate.

Is daraxonrasib available right now?

As of early June 2026, daraxonrasib is not yet commercially available. It can currently be accessed through enrollment in an ongoing clinical trial or through compassionate use authorization for selected patients who do not qualify for a trial. Regulatory review is in progress and approval is expected. If you or a family member has previously treated metastatic pancreatic cancer, ask your oncologist whether a trial or expanded access program may be an option.

Does daraxonrasib replace chemotherapy?

Not at this stage. Based on current evidence, daraxonrasib is used after patients have already received chemotherapy and experienced disease progression. It is not yet established as a first-line treatment. That may change: RASolute 303 is a phase 3 trial evaluating daraxonrasib as a first-line option for newly diagnosed metastatic pancreatic cancer, both as a standalone pill and in combination with standard chemotherapy. RASolute 304 is studying whether it can reduce the risk of recurrence in patients with resectable disease who have completed surgery and adjuvant chemotherapy. These trials will help determine how broadly daraxonrasib can eventually be used across the spectrum of pancreatic cancer care.

Reference: O’Reilly EM, Wainberg ZA, Hendifar AE, et al. Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer. N Engl J Med. Published May 31, 2026. DOI: 10.1056/NEJMoa2605555

This article is for educational purposes only and does not constitute medical advice. Treatment decisions should be made in consultation with your care team based on your individual situation.

← Back to Patient Education & News